Table 2.
IOP-lowering treatment effect at month 3 for the overall population, by time-matched IOP measurement, and by pre-study PGA
| n | IOP-lowering treatment effect mean (SD) mmHg | Difference in treatment effect mean (SD) mmHg [95% CI; P-value] | ||
|---|---|---|---|---|
| Pre-study PGA | SE travoprost intracameral implant | |||
| Overall population | 125 | −5.76 (3.43) | −7.07 (4.27) |
−1.31 (3.97) [−2.01, −0.60; P = 0.0003] |
| By time-matched IOP measurement | ||||
|
8:00 a.m Time-matched |
19 | −5.50 (3.17) | −6.37 (2.52) |
−0.87 (2.71) [−2.18, 0.44; P = 0.1798] |
|
10:00 a.m Time-matched |
55 | −5.65 (3.62) | −7.14 (5.03) |
−1.49 (4.50) [−2.71, −0.27; P = 0.0173] |
|
4:00 p.m Time-matched |
51 | −5.98 (3.38) | −7.25 (3.94) |
−1.27 (3.80) [−2.35, −0.20; P = 0.0207] |
| By pre-study PGA | ||||
| Latanoprost | 69 | −5.68 (3.27) | −7.26 (3.93) |
−1.58 (3.60) [−2.45, −0.71; P = 0.0005] |
| Bimatoprost | 27 | −6.11 (3.91) | −7.13 (3.50) |
−1.02 (3.50) [−2.40, 0.37; P = 0.1427] |
| Travoprost | 15 | −4.90 (3.60) | −5.17 (6.62) |
−0.27 (5.81) [−3.49, 2.95; P = 0.8615] |
| Latanoprostene bunod | 8 | −5.75 (3.34) | −6.06 (2.96) |
−0.31 (2.45) [−2.36, 1.73; P = 0.7288] |
| Tafluprost | 6 | −7.25 (3.17) | −10.67 (4.00) |
−3.42 (6.06) [−9.78, 2.94; P = 0.2259] |
CI confidence interval, IOP intraocular pressure, PGA prostaglandin analog, SD standard deviation, SE slow-eluting